Literature DB >> 10851045

The role of STATs in transcriptional control and their impact on cellular function.

J Bromberg1, J E Darnell.   

Abstract

The STAT proteins (Signal Transducers and Activators of Transcription), were identified in the last decade as transcription factors which were critical in mediating virtually all cytokine driven signaling. These proteins are latent in the cytoplasm and become activated through tyrosine phosphorylation which typically occurs through cytokine receptor associated kinases (JAKs) or growth factor receptor tyrosine kinases. Recently a number of non-receptor tyrosine kinases (for example src and abl) have been found to cause STAT phosphorylation. Phosphorylated STATs form homo- or hetero-dimers, enter the nucleus and working coordinately with other transcriptional co-activators or transcription factors lead to increased transcriptional initiation. In normal cells and in animals, ligand dependent activation of the STATs is a transient process, lasting for several minutes to several hours. In contrast, in many cancerous cell lines and tumors, where growth factor dysregulation is frequently at the heart of cellular transformation, the STAT proteins (in particular Stats 1, 3 and 5) are persistently tyrosine phosphorylated or activated. The importance of STAT activation to growth control in experiments using anti-sense molecules or dominant negative STAT protein encoding constructs performed in cell lines or studies in animals lacking specific STATs strongly indicate that STATs play an important role in controlling cell cycle progression and apoptosis. Stat1 plays an important role in growth arrest, in promoting apoptosis and is implicated as a tumor suppressor; while Stats 3 and 5 are involved in promoting cell cycle progression and cellular transformation and preventing apoptosis. Many questions remain including: (1) a better understanding of how the STAT proteins through association with other factors increase transcription initiation; (2) a more complete definition of the sets of genes which are activated by different STATs and (3) how these sets of activated genes differ as a function of cell type. Finally, in the context of many cancers, where STATs are frequently persistently activated, an understanding of the mechanisms leading to their constitutive activation and defining the potential importance of persistent STAT activation in human tumorigenesis remains. Oncogene (2000).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10851045     DOI: 10.1038/sj.onc.1203476

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  371 in total

Review 1.  Stat proteins and oncogenesis.

Authors:  Jacqueline Bromberg
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  Negative regulation of STAT92E by an N-terminally truncated STAT protein derived from an alternative promoter site.

Authors:  Melissa A Henriksen; Aurel Betz; Marc V Fuccillo; James E Darnell
Journal:  Genes Dev       Date:  2002-09-15       Impact factor: 11.361

Review 3.  Novel agents for chemoprevention, screening methods, and sampling issues.

Authors:  Mary Jo Fackler; Ella Evron; Seema A Khan; Saraswati Sukumar
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

4.  The antagonistic effect between STAT1 and Survivin and its clinical significance in gastric cancer.

Authors:  Hao Deng; Hongyan Zhen; Zhengqi Fu; Xuan Huang; Hongyan Zhou; Lijiang Liu
Journal:  Oncol Lett       Date:  2011-09-16       Impact factor: 2.967

Review 5.  IL-32θ: a recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity.

Authors:  Muhammad Babar Khawar; Maryam Mukhtar; Muddasir Hassan Abbasi; Nadeem Sheikh
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

6.  The role of STAT-3 in the induction of apoptosis in pancreatic cancer cells by benzyl isothiocyanate.

Authors:  Ravi P Sahu; Sanjay K Srivastava
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

7.  hCAF1/CNOT7 regulates interferon signalling by targeting STAT1.

Authors:  Clément Chapat; Chloé Kolytcheff; Muriel Le Romancer; Didier Auboeuf; Pierre De La Grange; Kamel Chettab; Stéphanie Sentis; Laura Corbo
Journal:  EMBO J       Date:  2013-02-05       Impact factor: 11.598

Review 8.  Immunobiology of hepatocarcinogenesis: Ways to go or almost there?

Authors:  Pavan Patel; Steven E Schutzer; Nikolaos Pyrsopoulos
Journal:  World J Gastrointest Pathophysiol       Date:  2016-08-15

9.  Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth.

Authors:  Paul L Leong; Genevieve A Andrews; Daniel E Johnson; Kevin F Dyer; Sichuan Xi; Jeffrey C Mai; Paul D Robbins; Seshu Gadiparthi; Nancy A Burke; Simon F Watkins; Jennifer Rubin Grandis
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-14       Impact factor: 11.205

10.  XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.

Authors:  Yan Cheng; Michael P Holloway; Kevin Nguyen; Dilara McCauley; Yosef Landesman; Michael G Kauffman; Sharon Shacham; Rachel A Altura
Journal:  Mol Cancer Ther       Date:  2014-01-15       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.